BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Earnings Results, Misses Expectations By $0.06 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06), Zacks reports. The business had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same period last year, the firm posted $0.28 EPS. The business’s revenue was up 40.8% on a year-over-year basis.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $8.28 on Wednesday. The firm has a 50 day moving average price of $8.05 and a 200 day moving average price of $7.85. The stock has a market cap of $1.72 billion, a P/E ratio of -13.57 and a beta of 1.75. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $9.50.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Barclays increased their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.